Oslo, Norway, May 27, 2022 - Lytix Biopharma AS ("Lytix" or the "Company"), a
clinical-stage company with an in situ vaccination technology platform,
announces that an abstract relating to LTX-315 in combination with Adoptive Cell
Therapy (ACT) has been selected for presentation at a Poster Session during
American Society of Clinical Oncology (ASCO) 2022. LTX-315 is a first-in-class
oncolytic molecule, representing a new and superior in situ therapeutic
vaccination principle to boost the clonal expansion of T cells and subsequent
anti-cancer immunity. 

Immune- and clinical response data from the Atlas-IT-04 trial will be presented
at the poster session. The trial is an open label, exploratory, Phase II trial
assessing the effect of LTX-315 when used in combination with ACT in patients
with metastatic soft tissue sarcoma (STS). The prognosis of advanced STS is poor
and with a high unmet medical need. In general STS have low number of tumor
infiltrating T cells and do not respond to immunotherapy. The trial design
includes intratumoral injections of LTX-315 ahead of surgical removal of tumors,
followed by in vitro expansion of T cells as the first step. In the second step,
the expanded T cells were infused back to the patients and the effect of LTX-315
on the tumor microenvironment was assessed. 

"This trial demonstrates that the combination of LTX-315 and ACT is feasible and
tolerable, and that CD4+ and CD8+ T cells can be expanded in vitro from STS that
have been pretreated with the oncolytic molecule LTX-315", CEO of Lytix, Øystein
Rekdal, comments. He adds: "We will now explore how further optimization of the
treatment schedule will position LTX-315 as promising technology to invoke tumor
specific T cells that can be cultured and infused as part of an adoptive
transfer regimen for several subtypes of soft tissue sarcoma."

At the time of the submission of the abstract, the complete data had not been
finally analyzed, and a revision of the data showed that there were three, not
four, patients with stable disease as best overall response.

The abstract will be presented June 5th at the ASCO 2022 annual meeting.
Poster Session: Sarcoma
Abstract: 11567
Poster: 471

The abstract can be found here
https://meetings.asco.org/abstracts-presentations/211276

For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358 
E-mail: Oystein.Rekdal@lytixbiopharma.com

Lytix Biopharma in brief: Based in Oslo, Norway, Lytix is a clinical stage
biotech company developing novel cancer immunotherapies, an area within cancer
therapy that is aimed at activating the patient's immune system to fight cancer.
The Company's technology is based on pioneering research in "host defense
peptides" - nature's first line of defense towards foreign pathogens. Lytix
Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule
representing a new and superior in situ therapeutic vaccination principle to
boost anti-cancer immunity, with the potential to be the ideal combination
partner with other types of immunotherapy. LTX-315 targets cancer cells and
disintegrates their cell membranes, causing immunogenic cell death and release
of a patient's tumor specific antigens. This mode of action allows cytotoxic T
cells to recognize, infiltrate and attack cancer cells.